T1	Participants 50 118	hyperglycemic patients with non-ST elevation acute coronary syndrome
T2	Participants 285 349	patients with diabetes receiving standard treatment for diabetes
T3	Participants 691 761	patients with diabetes and A1C of >or=8-10% at randomization (n = 171)
T4	Participants 968 1073	patients with FPG of 150-400 mg/dl at randomization, ranolazine (n = 131) compared with placebo (n = 147)
T5	Participants 862 888	placebo-adjusted (n = 182)
